Revolutionizing adherent cell assays to unlock better treatments for high unmet clinical needs and enable new research paradigms
Semarion has developed a novel class of materials, called SemaCytes®. These micro-scale cell carriers are uniquely engineered with microchip fabrication, nanomagnetism, and smart materials.
The core of our innovation lies in turning adherent cells into liquid reagents. Along with features such as assay miniaturization, barcoding, and automation, this facilitates better quality and more reproducible data, while reducing the time and cost to deliver research outputs.
Semarion has developed a novel class of materials, called SemaCytes®. These micro-scale cell carriers are uniquely engineered with microchip fabrication, nanomagnetism, and smart materials.
The core of our innovation lies in turning adherent cells into liquid reagents. Along with features such as assay miniaturization, barcoding, and automation, this facilitates better quality and more reproducible data, while reducing the time and cost to deliver research outputs.
Location: United Kingdom
Employees: 1-10
Total raised: $9.24M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Start Codo... | startcodon... |
| - | Parkwalk A... | parkwalkad... |
| 24.02.2022 | Martlet | martletcap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.04.2026 | - | $3.8M | - |
| 17.07.2025 | - | $2.52M | - |
| 24.02.2022 | Seed | $2.91M | Cambridge ... |
Mentions in press and media 20
| Date | Title | Description |
| 05.04.2026 | AI Compliance Innovator Variance Secures $21.5 Million Series A to Scale Enterprise Risk Management | Variance, a San Francisco-based AI pioneer, has secured $21.5 million in Series A funding. Ten Eleven Ventures spearheaded the round, with key participation from other prominent investors. This capital boost fuels Variance's mission to revo... |
| 02.04.2026 | Semarion Secures $3.8M to Propel Cell Assay Technology in Drug Discovery | Semarion, a pioneering Cambridge biotech firm, successfully raised $3.8 million. This strategic funding fuels the company's aggressive commercial expansion plans. It scales manufacturing of its groundbreaking SemaCyte platform. SemaCyte rev... |
| 01.04.2026 | Semarion: University of Cambridge Spin-Out Raises $3.8 Million To Scale Cell Assay Technology For Drug Discovery | Semarion, a University of Cambridge spin-out focused on advancing cell-based research, announced it has raised $3.8 million to expand its next-generation cell assay technology and accelerate adoption across the pharmaceutical industry. The ... |
| 01.04.2026 | Variance Raises $21.5M Series A Funding | Variance (fka Intrinsic), a San Francisco, CA-based company developing AI investigative agents for risk and compliance, raised $21.5M in Series A funding. The round was led by Ten Eleven Ventures, with participation from 645 Ventures, Y Com... |
| 01.04.2026 | Semarion Raises $3.8M in Funding | Semarion, a Cambridge, UK-based a biotechnology company which specializes in drug screening solutions, raised $3.8M in funding. The round was led by Parkwalk, with participation from the FSE Group, Cambridge Enterprise Ventures, Oxford Inno... |
| 31.03.2026 | Semarion raises $3.8M to scale cell assay technology | Semarion, a University of Cambridge spin-out from the Cavendish Laboratory, has raised $3.8 million in funding to support the expansion of its cell-based screening technology. The round was led by Parkwalk, with participation from The FSE G... |
| 17.07.2025 | Semarion secures £2.0m in latest funding round | We’re pleased to share that Parkwalk has participated in a £2.0m funding round for Semarion, a spin-out from the University of Cambridge’s Cavendish Laboratory. Semarion is commercialising its SemaCyte® platform, which transforms in-vitro c... |
| 19.06.2024 | As Cambridge Wide Open Day buzzes in 2024, get set for Cambridge Wide Open Week in 2025! | The 2nd annual Cambridge Wide Open Day (CWOD) event had Cambridge buzzing last week with curious residents as well as people attending from as far afield as Birmingham and Nottingham, and even Switzerland and the US! Initial figures suggest... |
| 18.10.2023 | Semarion announces Early Adopter Programme for SemaCyte Microcarrier Platform | SemaCyte Microcarrier Platform addresses limitations within adherent cell assays to accelerate the pace of in vitro drug discovery Early access will further validate the technology and provide feedback on applicability across customer workf... |
| 07.02.2023 | #21toWatch announces shortlist of next generation of Cambridge game-changers set for future success | cofinitive have announced the shortlist for #21toWatch 2023 which this year contains an eclectic mix of industries – biotech, cleantech, agritech, construction, automotive, deep learning, marine, life sciences, AI – all sharing the same mis... |
Show more